• Should I get gene testing if I am planning to become pregnant?
    Noninvasive prenatal screening can identify your risks for passing down an inherited condition such as cystic fibrosis or spinal muscular atrophy to your baby. Planning for your future family now provides the opportunity to understand potential genetic risks.
  • Should I get tested for hereditary cancer if my mother or a close relative had it?
    Approximately 1 in 4 patients in the community OBGYN setting may be at risk for hereditary cancer and meet current screening guidelines for testing. Screening and subsequent interventions have been shown to reduce risk.
  • What type of gene testing does Myriad offer for women’s health?
    Myriad offers three different categories of testing for women: cancer risk assessment with MyRisk, inherited conditions for family planning with ForeSight, and prenatal screening with Prequel.
  • What if my Prequel Prenatal Screen test results come back positive?
    If your screen turns up something unusual, your healthcare provider will discuss what it means and will offer a follow-up diagnostic procedure to confirm the results. This may be chorionic villus sampling (CVS) or amniocentesis.
  • How early can Prequel Prenatal Screen be used to identify increased risk for conditions like Down Syndrome?
    Patients can use Prequel as early as ten weeks into their pregnancy to identify an increased risk for a chromosome abnormality associated with a certain genetic condition.
  • What does the Myriad Prequel test do?
    The Myriad Prequel Prenatal Screen is a noninvasive screen ordered by your healthcare provider when you are pregnant to learn about your baby’s chance of having a chromosome abnormality leading to a condition like Down syndrome.
  • How reliable is MyChoice CDx?
    MyChoice CDx identifies ~34% more tumors with HRD than %LOH alone.
  • What is HRD status?
    Homologous recombination (HR) is the way our body fixes damaged DNA. When homologous recombination is not able to fix damaged DNA, this is called homologous recombination deficiency (HRD). Approximately 50% of all ovarian cancer tumors have homologous recombination deficiency.
  • What is MyChoice CDx?
    MyChoice CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status. It is the most comprehensive tumor test to determine HRD status in patients with ovarian cancer.
  • How can BRACAnalysis CDx help my patients?
    BRACAnalysis CDx provides fast and accurate BRCA1/2 results. Germline BRCA1 and BRCA2 status is a critical biomarker to help you determine the appropriate therapy for your patients with breast, ovarian, pancreatic, and prostate cancer.
  • What does BRACAnalysis CDx test for?
    BRACAnaysis CDx is the only FDA-targeted therapy used to detect mutations in BRCA1 or BRCA2 genes. Mutations in these genes can influence breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Early detection can help you and your healthcare provider the best healthcare decisions for your future care.
  • What is BRCA?
    Everyone is born with BRCA genes. Normally, the proteins produced by the BRCA1 and BRCA2 genes prevent cells from developing into cancer. When one of these genes becomes ineffective due to an inherited mutation, the cell can no longer prevent tumors from growing, causing an increased risk for cancer.
  • What does BRACAnalysis test for?
    BRACAnalysis tests for a mutation in specific genes to determine hereditary breast or ovarian cancer risk.
  • How do MyRisk and MyScore work together?
    MyRisk and MyScore work together to provide information on hereditary cancer genes, personal and family history, breast cancer genetic risk markers, and ancestry genetic risk markers.
  • How does Myriad RiskScore work?
    RiskScore is the only breast cancer risk assessment test that incorporates the patient’s own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers.

Any more questions? We are here for you!